{"id":387525,"date":"2020-11-24T08:03:29","date_gmt":"2020-11-24T13:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387525"},"modified":"2020-11-24T08:03:29","modified_gmt":"2020-11-24T13:03:29","slug":"icad-reports-over-1000-licenses-sold-as-part-of-profound-ai-sales","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/icad-reports-over-1000-licenses-sold-as-part-of-profound-ai-sales\/","title":{"rendered":"iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales"},"content":{"rendered":"
\n

\n
\n Significant Percentage <\/em>
\n <\/strong>
\n
\n of Licenses <\/em>
\n <\/strong>
\n
\n Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and <\/em>
\n <\/strong>
\n
\n Fuji<\/em>
\n <\/strong>
\n \n <\/p>\n

\n
\n ProFound AI <\/em>
\n <\/strong>
\n
\n for DBT Offers<\/em>
\n <\/strong>
\n
\n Superior <\/em>
\n <\/strong>
\n
\n Clinical <\/em>
\n <\/strong>
\n
\n Performance <\/em>
\n <\/strong>
\n
\n When Compared to Other Commercially Available Breast AI Systems <\/em>
\n <\/strong>\n <\/p>\n

NASHUA, N.H., Nov. 24, 2020 (GLOBE NEWSWIRE) — iCAD<\/u>, Inc<\/u><\/a>. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported that over 1,000 licenses have been sold as part of ProFound AI\u00ae sales since the products were launched, signaling the rapid and wide-spread adoption of the pioneering cancer detection software solution built on artificial intelligence (AI). The sales have been distributed across all major mammography system vendors and enterprise-wide viewing applications with a significant percentage to date sold to hospitals and imaging centers with GE and Siemens, as well as facilities with more than one imaging system vendor, including Hologic and Fuji.<\/p>\n

The solid momentum is led by the Company\u2019s growing customer base and demand for its expanded suite of leading breast health AI solutions<\/u><\/a>, including ProFound AI for both Digital Breast Tomosynthesis (DBT) and 2D mammography, and interest in the recently introduced ProFound AI Risk, which is helping to transform breast cancer screening from age-based screening to risk-adapted precision screening, individualized for each woman.<\/p>\n

\u201ciCAD offers the full continuum of breast health AI products\u2014both for the detection of current breast cancers and for future risk assessment,\u201d said Michael Klein<\/u><\/a>, Chairman and CEO of iCAD. \u201cWe do so on a non-exclusive, open architecture basis, therefore allowing all global customers access to the best of breed AI software available. Of significant note is that no other breast AI solution has been shown to improve radiologists\u2019 clinical performance when reading DBT more so than ProFound AI. Specifically, our high-performing cancer detection and workflow solution offers the highest cancer detection rate, the lowest false positive rate and a dramatic 52.7% reduction in radiologists\u2019 reading time, representing a high level of clinical significance and advantage.\u201d<\/p>\n

According to Kathy Schilling, MD, Medical Director of the Christine E. Lynn Women\u2019s Health & Wellness Institute at the Boca Raton Regional Hospital, \u201cProFound AI for DBT rapidly and accurately analyze patients\u2019 DBT mammography images, identifying suspicious lesions and producing quantifiable AI scores, which enables us to identify cancers earlier. The software also improves workflow issues, as we\u2019re able to more quickly navigate through DBT datasets.\u201d<\/p>\n

ProFound AI Risk is the first and only commercially available clinical decision support tool to provide an accurate two-year breast cancer risk estimation based solely on a screening mammogram. Compelling research published in the peer-reviewed journal, Radiology<\/u><\/a><\/em> concluded that the ProFound AI Risk model is effective at identifying women at high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.<\/p>\n

\u201cI was very enthusiastic about the launch of ProFound AI Risk, which I believe is more accurate than the other risk tools I\u2019ve used, and it is very easy to integrate into my daily workflow,\u201d said Carine Van De Merckt, MD, Radiologist at Institut Jules Bordet in Brussels, Belgium. \u201cFurthermore, it has proven to help me in my clinical decision making, allowing me to continue to provide the best care to my patients with even more confidence.\u201d<\/p>\n

As part of the Company\u2019s growth, iCAD has recently achieved significant milestones, including:<\/p>\n